<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434692</url>
  </required_header>
  <id_info>
    <org_study_id>ARGOS-02</org_study_id>
    <secondary_id>CIV-13-11-011719</secondary_id>
    <nct_id>NCT02434692</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)</brief_title>
  <official_title>A Prospective, Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of the ARGOS-IO System in Patients With Primary Open Angle Glaucoma (POAG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Implandata Ophthalmic Products GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Implandata Ophthalmic Products GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in&#xD;
      patients with POAG and indicated cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, open-label, multi center, single-arm clinical investigation will enroll 22&#xD;
      consecutive patients.&#xD;
&#xD;
      Enrollment will be temporarily halted in case a serious adverse device effect (SADE) occurs,&#xD;
      and Data and Safety Monitoring Board (DSMB) meeting will be conducted as soon as possible.&#xD;
      The DSMB will then recommend whether to further continue the study as planned, or whether&#xD;
      enrollment shall be stopped. In order to provide a complete overview of the study to the&#xD;
      DSMB, an interim analysis will be performed after half of the study population (11-14&#xD;
      subjects) is enrolled with a minimum follow-up of 1 month. A conclusion for safety will be&#xD;
      made if in total no more than 2 of the total of 22 patients experience a SADE.&#xD;
&#xD;
      The primary aim of this study is to show &quot;safety&quot;, which will be evaluated based on the&#xD;
      percentage of subjects who experience a SADE (=&quot;non-safety&quot;), as defined in the primary&#xD;
      endpoints.&#xD;
&#xD;
      The study will be declared a success if the final non-safety event rate is less than 6% (type&#xD;
      II error rate of 0.20). The calculation is based on a design optimizing the minimum expected&#xD;
      sample size with parameters alpha=0.05, beta=0.20, p0=0.75, p1=0.94.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">April 11, 2017</completion_date>
  <primary_completion_date type="Actual">April 11, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients experiencing a device related serious adverse event (SAE) defined as any adverse event that both&#xD;
Is considered by the Investigator to have a possible, probable or definite relationship to the device and&#xD;
That meets any of the following criteria of a serious adverse event:&#xD;
Resulted in death, permanent damage or disability or a congenital anomaly&#xD;
Was life threatening&#xD;
Required hospitalization or intervention to prevent permanent impairment or damage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of observed adverse events and adverse device events during a period between 3 months and 12 months following implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Severity of observed adverse events and adverse device events during a period between 3 months and 12 months following implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>12 months</time_frame>
    <description>Limits of agreement between measurements made using GAT and the ARGOS-IO system from V05 (day 30) through V11 (day 360)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Primary Open Angle Glaucoma (POAG)</condition>
  <arm_group>
    <arm_group_label>Single-arm intervention ARGOS-IO system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ARGOS-IO Pressure sensor will be additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARGOS-IO system</intervention_name>
    <description>Implantation of ARGOS-IO pressure sensor after cataract surgery on day 0 (V01)</description>
    <arm_group_label>Single-arm intervention ARGOS-IO system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Mentally competent and willing to provide written informed consent&#xD;
&#xD;
          2. Male or female aged ≥40 and ≤85 years. Female subjects of childbearing potential must&#xD;
             be willing to use adequate contraception and must have a negative pregnancy test.&#xD;
&#xD;
          3. Diagnosis of primary open-angle glaucoma (POAG) including high pressure glaucoma&#xD;
             (HPG), normal pressure glaucoma (NPG) and ocular hypertension (OH), as defined by the&#xD;
             European Glaucoma Society guideline (Heijl, Treverso, et al., 2008)&#xD;
&#xD;
          4. Sufficiently controlled intraocular pressure (IOP)&#xD;
&#xD;
          5. Study eye needs to be phakic&#xD;
&#xD;
          6. Only one eye per patient may be implanted with the ARGOS-IO implant&#xD;
&#xD;
          7. Cataract surgery indicated. The medical indication for a cataract operation must be&#xD;
             given irrespective of the study participation. Potential study patients will be&#xD;
             solicited for participation in the clinical trial only after the patient has given&#xD;
             consent to the cataract operation.&#xD;
&#xD;
          8. Pre-operative anterior chamber depth (ACD) ≥2.0 mm as measured from the corneal&#xD;
             endothelium&#xD;
&#xD;
          9. Axis length &gt;22 mm&#xD;
&#xD;
         10. Endothelial cell density of the cornea ≥2000 cells/mm²&#xD;
&#xD;
         11. Subjects able and willing to attend all scheduled visits and comply with all study&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other type of glaucoma other than primary open-angle glaucoma as defined by&#xD;
             inclusion criterion 3&#xD;
&#xD;
          2. Severe POAG patients with a macular degeneration and visual field loss of -20 decibels&#xD;
             (dB) or worse in both eyes. In case of a diverse developed visual field loss, the&#xD;
             sensor can be implanted in the worse eye for protection the better eye.&#xD;
&#xD;
          3. Exudative age-related macular degeneration, instable macular degeneration 30 days&#xD;
             prior to inclusion, or macular edema&#xD;
&#xD;
          4. Retinal detachment&#xD;
&#xD;
          5. Corneal diseases, especially diseases affecting the corneal endothelium, e.g. Fuchs'&#xD;
             Dystrophia&#xD;
&#xD;
          6. Diabetes mellitus&#xD;
&#xD;
          7. Existence of Marfan-Syndrome, Ehlers-Danlos-Syndrome or Weill-Marchesani-Syndrome&#xD;
&#xD;
          8. History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis,&#xD;
             scleritis) in one or both eyes within 6 months prior to ARGOS-IO implantation&#xD;
&#xD;
          9. Intraocular surgical procedure(s) within 6 months prior to ARGOS-IO implantation or&#xD;
             any surgical procedure such as refractive eye surgery in the study eye that can affect&#xD;
             the assessment of IOP by Goldmann applanation tonometry&#xD;
&#xD;
         10. History of eye tumor&#xD;
&#xD;
         11. Ocular disease other than glaucoma that may affect assessment of visual acuity and/or&#xD;
             IOP by Goldmann applanation tonometry (choroidal hemorrhage or detachment, lens&#xD;
             subluxation, thyroid ophthalmopathy)&#xD;
&#xD;
         12. Anterior chamber configuration that puts the subject at high risk to develop an angle&#xD;
             closure glaucoma&#xD;
&#xD;
         13. History of extensive keloid formation&#xD;
&#xD;
         14. Severe dry eye syndrome&#xD;
&#xD;
         15. Subjects who will need to undergo ancillary procedures in the study eye at the time of&#xD;
             implantation or during the post-operative study period&#xD;
&#xD;
         16. Any known intolerance or hypersensitivity to topical anesthetics, mydriatics, plaster&#xD;
             or silicone (component of the device)&#xD;
&#xD;
         17. Existence of other active medical eye implant and/or other active medical implants in&#xD;
             the head/neck region&#xD;
&#xD;
         18. Any contraindication for intraocular lens (IOL) implantation such as choroidal&#xD;
             hemorrhage, concomitant severe eye disease, excessive vitreous loss, extremely shallow&#xD;
             anterior chamber, microphthalmos, non-age-related cataract, posterior capsular&#xD;
             rupture, severe corneal dystrophy, untraceable IOP, zonular separation, color vision&#xD;
             deficiencies&#xD;
&#xD;
         19. Severe generalized disease resulting in a life expectancy shorter than a year&#xD;
&#xD;
         20. Any clinical evidence that the investigator feels would place the subject at increased&#xD;
             risk with the placement of the device&#xD;
&#xD;
         21. Currently pregnant or breastfeeding&#xD;
&#xD;
         22. Participation in any study involving an investigational drug or device within the past&#xD;
             30 days or ongoing participation in a study with an investigational drug or device&#xD;
&#xD;
         23. Patients who are not suitable for the study based on the surgeon's evaluation&#xD;
&#xD;
         24. Patients unable or unwilling to understand or comply with required study procedures&#xD;
&#xD;
         25. Patients with psychiatric disorders influencing their judgement or autonomy&#xD;
&#xD;
         26. Subject and/or an immediate family member is an employee of the investigational site&#xD;
             directly affiliated with this study, the sponsor or the contract research&#xD;
             organization.&#xD;
&#xD;
         27. Enrollment of the fellow eye in this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagen Thieme, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Eye Clinic Magdeburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Augenklinik Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augen-Zentrum-Nordwest</name>
      <address>
        <city>Ahaus</city>
        <zip>48683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internationale Innovative Ophthalmochirurgie Breyer-Kaymak-Klabe</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenklinik der SLK-Kliniken</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>nordBLICK Augenklinik Bellevue</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsaugenklinik Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenärztliches Augenchirurgisches Zentrum (AAZ)</name>
      <address>
        <city>Nürnberg</city>
        <zip>90403</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Augenheilkunde der Universität Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftsklinikum Saar - Augenklinik</name>
      <address>
        <city>Sulzbach</city>
        <zip>66280</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Open Angle Glaucoma</keyword>
  <keyword>POAG</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Cataract</keyword>
  <keyword>Surgery</keyword>
  <keyword>Ocular Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

